{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:32:50Z","timestamp":1793385170259,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,28]],"date-time":"2027-08-28T00:00:00Z","timestamp":1819411200000},"content-version":"am","delay-in-days":270,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["KL2 TR002379"],"award-info":[{"award-number":["KL2 TR002379"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002014"],"award-info":[{"award-number":["UL1 TR002014"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR00045"],"award-info":[{"award-number":["UL1 TR00045"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jad.2026.122407","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T14:43:20Z","timestamp":1787409800000},"page":"122407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study"],"prefix":"10.1016","volume":"414","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7062-8192","authenticated-orcid":false,"given":"Balwinder","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feyza","family":"Yaylaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritika","family":"Baweja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria L.","family":"Gonzalez Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Baweja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2026.122407_bb0005","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.2337\/dc25-S008","article-title":"8. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of care in diabetes-2025","volume":"48","author":"American Diabetes Association Professional Practice, C","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2026.122407_bb0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jad.2026.122407_bb0020","article-title":"Attention-deficit\/hyperactivity disorder treatment patterns and association with clinical outcomes in adolescents and young adults with co-occurring attention-deficit\/hyperactivity disorder and substance use disorder: a retrospective analysis","author":"Baweja","year":"2025","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2026.122407_bb0025","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes Management in Chronic Kidney Disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jad.2026.122407_bb0030","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s40620-023-01599-8","article-title":"Chronic kidney disease and severe mental illness: a scoping review","volume":"36","author":"Carswell","year":"2023","journal-title":"J. Nephrol."},{"key":"10.1016\/j.jad.2026.122407_bb0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2215\/CJN.15691221","article-title":"Chronic kidney disease and severe mental illness: addressing disparities in access to health care and health outcomes","volume":"17","author":"Cogley","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jad.2026.122407_bb0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"10.1016\/j.jad.2026.122407_bb0045","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40263-022-00952-y","article-title":"Psychotropic drugs and adverse kidney effects: a systematic review of the past decade of research","volume":"36","author":"Damba","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jad.2026.122407_bb0050","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2024.06.016","article-title":"Kidney and cardiovascular effectiveness of SGLT2 inhibitors vs GLP-1 receptor agonists in type 2 diabetes","volume":"84","author":"Edmonston","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jad.2026.122407_bb0055","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.mayocp.2024.10.008","article-title":"Lithium and kidney disease","volume":"100","author":"Ercis","year":"2025","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.jad.2026.122407_bb0060","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Group, T.E.-K.C","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamasurg.2022.7753","article-title":"Comparing kidney transplant rates and outcomes among adults with and without intellectual and developmental disabilities","volume":"158","author":"Hand","year":"2023","journal-title":"JAMA Surg."},{"key":"10.1016\/j.jad.2026.122407_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1053\/j.ajkd.2025.03.012","article-title":"Severe mental illness in CKD: why it matters","volume":"85","author":"Hedayati","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jad.2026.122407_bb0075","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0080","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jad.2026.122407_bb0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1001\/jamainternmed.2025.7409","article-title":"SGLT2 inhibitors vs GLP-1 receptor agonists for kidney outcomes in individuals with type 2 diabetes","volume":"186","author":"Jensen","year":"2026","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0090","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes, C.K.D.W.G","year":"2024","journal-title":"Kidney Int."},{"key":"10.1016\/j.jad.2026.122407_bb0095","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.ajkd.2025.03.016","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists and sodium\/glucose cotransporter 2 inhibitors in preventing chronic kidney failure and mortality in patients with type 2 diabetes and CKD","volume":"86","author":"Lee","year":"2025","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jad.2026.122407_bb0100","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jad.2021.12.110","article-title":"Prevalence of type 2 diabetes mellitus, impaired fasting glucose, general obesity, and abdominal obesity in patients with bipolar disorder: a systematic review and meta-analysis","volume":"300","author":"Liu","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122407_bb0105","first-page":"1","article-title":"Nephroprotective effects of GLP-1 receptor agonists in lithium-treated patients: a multinational cohort study using the TriNetX network","author":"McIntyre","year":"2026","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2026.122407_bb0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.122407_bb0115","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1002\/sim.7019","article-title":"Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study","volume":"35","author":"Mi","year":"2016","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0120","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s13300-025-01829-1","article-title":"Rewriting diabetes therapy: how incretin modulation is transforming cardiovascular and renal outcomes","volume":"17","author":"Miramontes-Gonzalez","year":"2026","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.jad.2026.122407_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-004251","article-title":"Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study","volume":"4","author":"Neovius","year":"2014","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.jad.2026.122407_bb7000","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bdi.13052","article-title":"Long-term lithium therapy and risk of chronic kidney disease in bipolar disorder: A historical cohort study","volume":"23","author":"Pahwa","year":"2021","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2026.122407_bb0130","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50050","article-title":"Sodium-glucose cotransport protein 2 inhibitors in patients with type 2 diabetes and acute kidney disease","volume":"7","author":"Pan","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2026.122407_bb0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2026.122407_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfaf116.0511","article-title":"The effect of GLP-1 receptor agonists on renal outcomes: a systematic review and meta-analysis","author":"Sasaki","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.jad.2026.122407_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40842-025-00248-2","article-title":"Effectiveness of SGLT2 inhibitors, incretin-based therapies, and finerenone on cardiorenal outcomes: a meta-analysis and network meta-analysis","volume":"11","author":"Shokravi","year":"2025","journal-title":"Cardiovasc. Diabetol. Endocrinol. Rep."},{"key":"10.1016\/j.jad.2026.122407_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2026.121702","article-title":"Association of SGLT2 inhibitors with suicidality, all-cause mortality, and hospitalization in bipolar disorder: a cohort study of 1.23 million adults","volume":"406","author":"Singh","year":"2026","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.122407_bb0155","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(25)01140-7","article-title":"Bipolar disorder","volume":"406","author":"Singh","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2026.122407_bb0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.26m16392","article-title":"GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease","author":"Singh","year":"2026","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.122407_bb0165","doi-asserted-by":"crossref","DOI":"10.1177\/20451253261423437","article-title":"Sodium-glucose cotransporter-2 inhibitors lower risk of kidney replacement therapy and mortality in bipolar disorder with chronic kidney disease","volume":"16","author":"Singh","year":"2026","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.122407_bb0170","doi-asserted-by":"crossref","DOI":"10.1186\/s13098-026-02195-z","article-title":"Metformin versus DPP-4 inhibitors and risk of Parkinsonism in type 2 diabetes: an active-comparator cohort study with a landmark design","volume":"18","author":"Sun","year":"2026","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.jad.2026.122407_bb0175","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1111\/j.1742-1241.2007.01416.x","article-title":"Metabolic side effects of antipsychotic medication","volume":"61","author":"Tschoner","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2026.122407_bb0180","series-title":"Chronic Kidney Disease","author":"Vaidya","year":"2026"},{"key":"10.1016\/j.jad.2026.122407_bb0185","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"key":"10.1016\/j.jad.2026.122407_bb0190","first-page":"672","article-title":"Comparison of the effects of SGLT-2i versus GLP-1RA on cardiovascular and renal outcomes in patients with type 2 diabetes, based on baseline renal function","volume":"74","author":"Wang","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.jad.2026.122407_bb0195","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2022.12.015","article-title":"Kidney and cardiovascular effects of Canagliflozin according to age and sex: a post hoc analysis of the CREDENCE randomized clinical trial","volume":"82","author":"Yi","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.jad.2026.122407_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156433","article-title":"GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis","volume":"175","author":"Zhang","year":"2026","journal-title":"Metabolism"},{"key":"10.1016\/j.jad.2026.122407_bb0205","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2018.3024","article-title":"Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"319","author":"Zheng","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2026.122407_bb0210","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2024.12.004","article-title":"Prevalence of severe mental illness and its associations with health outcomes in patients with CKD: a Swedish nationwide study","volume":"85","author":"Zhu","year":"2025","journal-title":"Am. J. Kidney Dis."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726012607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726012607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:00:35Z","timestamp":1793383235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726012607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":43,"alternative-id":["S0165032726012607"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.122407","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.122407","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"122407"}}